DatabaseCortagen
Tier 4NeuroprotectionAnti-agingNootropicPREMIUM

Cortagen

Cortagen (Ala-Glu-Asp-Pro / AEDP)
Not approved anywhere. No FDA designation. Research compound only. Not WADA-listed as of 2026.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide derived from bovine brain cortex extract (Cortexin), developed by Vladimir Khavinson's group in St. Petersburg. It is proposed to remodel chromatin and reactivate silenced genes in neural and cardiac tissue. Rat studies show 27% faster nerve fiber growth and 40% higher conduction velocity after sciatic nerve transection. No published, peer-reviewed human clinical trial exists. A 2004 background-section claim of human therapeutic use has no primary citation and cannot be treated as clinical evidence. This is a Tier 4 compound.

🔒

Full Profile: Premium Members Only

The complete Cortagen profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use